Seneca Biopharma, Inc. (SNCA)
Stock Price:
$0.710 USD
-0.014 (-1.93%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
12.28M |
| Revenue (ttm) |
13,520 |
| Net Income (ttm) |
-13.33M |
| Shares Out |
17.30M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$0.710 |
| Previous Close |
$0.724 |
| Change ($) |
-0.014 |
| Change (%) |
-1.93% |
| Day's Open |
0.730 |
| Day's Range |
0.700 - 0.740 |
| Day's Volume |
362,138 |
| 52-Week Range |
0.500 - 4.090 |
More Stats
| Market Cap |
12.28M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.30M |
| Float |
16.26M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-0.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
17,170 |
| Short Ratio |
0.09 |
| Short % of Float |
0.42% |
| Beta |
1.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
908.28 |
| PB Ratio |
1.47 |
| Revenue |
13,520 |
| Operating Income |
-8.19M |
| Net Income |
-13.33M |
| Free Cash Flow |
-7.69M |
| Net Cash |
15.67M |
| Net Cash / Share |
0.91 |
| Gross Margin |
113.86% |
| Operating Margin |
-60,610.70% |
| Profit Margin |
-98,571.70% |
| FCF Margin |
-56,888.63% |
| ROA |
-49.05% |
| ROE |
-146.47% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
520
Current: $0.710
High
520
Target: 520.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.02 | 0.26 | 0.26 | 0.02 | 0.01 | 0.02 | 0.11 | 0.41 | 0.39 | 0.73 |
| Revenue Growth | -94.08% | 0% | 1500.39% | 55.96% | -44.69% | -82.88% | -73.02% | 4.37% | -46.74% | - |
| Gross Profit | 0.02 | 0.26 | 0.26 | 0.02 | 0.01 | 0.02 | 0.11 | 0.41 | 0.39 | 0.73 |
| Operating Income | -8.63 | -8.26 | -13.31 | -20.64 | -19.16 | -17.44 | -12.52 | -10.16 | -12.99 | -15.18 |
| Net Income | -8.35 | -4.92 | -15.67 | -21.07 | -20.90 | -22.63 | -19.83 | -10.12 | -12.52 | -18.39 |
| Shares Outstanding | 2.20 | 0.65 | 0.65 | 0.42 | 0.35 | 0.33 | 0.28 | 0.22 | 0.19 | 0.17 |
| Earnings Per Share | -3.80 | -7.54 | -23.98 | -50.60 | -59.80 | -67.60 | -70.20 | -44.20 | -67.60 | -109.20 |
| Operating Cash Flow | -7.26 | -7.69 | -13.42 | -15.62 | -18.93 | -11.71 | -10.59 | -8.48 | -8.10 | -9.98 |
| Capital Expenditures | - | - | -0.01 | -0.10 | -0.18 | -0.21 | -0.13 | -0.04 | -0.20 | -0.33 |
| Free Cash Flow | -7.26 | -7.69 | -13.43 | -15.71 | -19.11 | -11.91 | -10.72 | -8.52 | -8.29 | -10.31 |
| Cash & Equivalents | 5.11 | 5.79 | 11.67 | 20.19 | 12.23 | 27.53 | 16.85 | 7.44 | 2.35 | 9.26 |
| Total Debt | 0.41 | 0.22 | - | 3.71 | 7.93 | 8.79 | 9.11 | - | - | - |
| Net Cash / Debt | 4.70 | 5.57 | 11.67 | 16.49 | 4.31 | 18.74 | 7.73 | 7.44 | 2.35 | 9.26 |
| Assets | 6.58 | 7.68 | 13.88 | 22.60 | 14.95 | 29.84 | 19.41 | 8.75 | 4.09 | 10.59 |
| Liabilities | 1.46 | 1.63 | 5.37 | 11.27 | 9.98 | 12.12 | 11.00 | 1.78 | 2.43 | 2.74 |
| Book Value | 5.13 | 6.05 | 8.52 | 11.33 | 4.97 | 17.72 | 8.42 | 6.97 | 1.66 | 7.85 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Seneca Biopharma, Inc. |
| Country |
United States |
| Employees |
7 |
| CEO |
Kenneth C. Carter |
Stock Information
| Ticker Symbol |
SNCA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SNCA |
Description
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.